Gerresheimer AG has decided to separate and initiate the sale of its Moulded Glass business following a strategic review aimed at evaluating growth and competitiveness opportunities. The company concluded that the best path forward for the newly formed "Moulded Glass Powerhouse" lies outside the Gerresheimer Group. CEO Dietmar Siemssen stated that this move aligns with the company’s transformation strategy, which emphasizes a stronger focus on providing systems and solutions for the pharmaceutical and biotech industries.

The decision comes after Gerresheimer’s recent acquisition of Bormioli Pharma, which played a key role in creating the integrated Moulded Glass business. This division now includes eight manufacturing plants across Germany, Belgium, Italy, the United States, and India, employing approximately 3,700 people. In the 2024 financial year, it generated pro forma revenues of around EUR 735 million and an adjusted EBITDA margin of about 20%. The business offers a wide range of type I, II, and III glass packaging products for the pharmaceutical, cosmetics, and food and beverage sectors.

Significant investments have been made in modernising the unit, including a EUR 100 million upgrade to the Lohr am Main facility in Germany, which features an energy-efficient oxy-hybrid furnace. Over the past months, Gerresheimer has worked to structure the Moulded Glass division as an independent global entity in preparation for this transition.

The formal separation process will now begin, with a sales process to follow. Further details are expected during Gerresheimer’s Capital Markets Day on October 15, 2025. This move underscores the company’s strategy to evolve into a focused provider of drug delivery systems, biologics packaging, and pharma-biotech solutions.